Provided by Tiger Trade Technology Pte. Ltd.

Abeona Therapeutics

4.85
-0.1500-3.00%
Post-market: 4.860.0100+0.21%19:38 EST
Volume:1.01M
Turnover:4.97M
Market Cap:262.83M
PE:3.77
High:5.09
Open:5.04
Low:4.80
Close:5.00
52wk High:7.54
52wk Low:3.93
Shares:54.19M
Float Shares:38.26M
Volume Ratio:0.69
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.29
EPS(LYR):-1.5527
ROE:75.90%
ROA:-29.57%
PB:1.53
PE(LYR):-3.12

Loading ...

Abeona Therapeutics (ABEO): Assessing Value After J-Code Milestone for ZEVASKYN Approval

Simply Wall St.
·
Nov 12

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

GlobeNewswire
·
Nov 07

Abeona Therapeutics Grants 71,035 Restricted Shares to New Employees

Reuters
·
Nov 03

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 03

BRIEF-Abeona Therapeutics Announces Permanent J-Code For Zevaskyn(Prademagene Zamikeracel)

Reuters
·
Oct 31

Abeona Therapeutics Inc - New J-Code J3389 for Zevaskyn Effective January 1, 2026

THOMSON REUTERS
·
Oct 30

Abeona Therapeutics® Announces Permanent J-Code for Zevaskyn® (Prademagene Zamikeracel)

THOMSON REUTERS
·
Oct 30

CMS Assigns Permanent J-Code to Abeona Therapeutics’ ZEVASKYN

Reuters
·
Oct 30

Vogo SA Releases Response Note on Offer Initiated by ABEO

Reuters
·
Oct 24

Abeona Therapeutics® Appoints James a. Gow, Md, MBA, MS, Mhcm, as Senior Vice President, Head of Clinical Development & Medical Affairs

THOMSON REUTERS
·
Oct 20

Press Release: Abeona Therapeutics(R) Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Dow Jones
·
Oct 20

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Reuters
·
Oct 14

BUZZ-Abeona rises as US FDA picks its eye disease gene therapy for pilot program

Reuters
·
Oct 13

Abeona Therapeutics® Announces Abo-503 Gene Therapy for X-Linked Retinoschisis (Xlrs) Selected by FDA for Rare Disease Endpoint Advancement (Rdea) Pilot Program

THOMSON REUTERS
·
Oct 13

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

GlobeNewswire
·
Oct 13

Abeona Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 13

Abeona Therapeutics (ABEO) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Oct 13

Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN

TIPRANKS
·
Oct 08

Top Executives Offload Abeona Therapeutics Stock in Major Sell-Off!

TIPRANKS
·
Oct 02

BRIEF-Abeona Therapeutics Announces New Employee Inducement

Reuters
·
Oct 01